期刊文献+

三种方法测定肌钙蛋白Ⅰ分析性能的比较与评价 被引量:4

Performances of Three Methods for the Detection of Troponin-Ⅰ
下载PDF
导出
摘要 用化学发光法、胶体金法及胶乳增强免疫比浊法测定60例肌钙蛋白I(cTnI),评价三种方法的分析性能及测定结果的差异及相关性,以便临床根据需要选择合适的方法测定cTnI。通过本次评价发现,胶体金法及化学发光法与临床诊断有很好的总符合率,且灵敏度、特异性较高,误诊率和漏诊率低。三种检测方法测定结果之间有显著性差异,P<0.001,两两比较,胶乳法与胶体金法、化学发光法之间有显著性差异,P值均<0.001;胶体金和化学发光法之间没有显著性差异,P=0.986。胶体金法(Y1)与化学发光法(X)相关性好,Y1=1.20X-0.11,R2=0.933;相关性优于胶乳增强免疫比浊法(Y2),Y2=3.65X+0.49,R2=0.892。在分析性能上胶体金法测定cTnI优于胶乳增强免疫比浊法,且与化学发光法有较好的相关性,适用于急诊及床旁检测。 To evaluate the performance of three different methods on the detection of Troponin-Ⅰ,the serum Troponin-Ⅰ levels in 60 samples were detected by chemiluminescence immunoassay(CLIA),Colloidal gold colloid immunochromatography assay(CGCIA) and latex enhanced immunoturbidimetric assay(LEITD) respectively.The results showed that the results measured by CLIA and CGCIA matched with clinical diagnosis verification very well,with high coincidence,sensitivity,and specificity.The results measured by three methods had significant difference(P0.001).When compared with each other,the results between CLIA and CGCIA have no differences,while the results of CLIA and CGCIA between LEITD were different(P0.001).The results measured by CGCIA were better correlated with CLIA.The performance of CGCIA is better than LEITD,especially in the emergency clinical laboratory and Point of Care Testing.
出处 《标记免疫分析与临床》 CAS 2010年第5期321-323,共3页 Labeled Immunoassays and Clinical Medicine
关键词 肌钙蛋白Ⅰ 胶体金法 胶乳增强免疫比浊法 化学发光法 性能评价 Troponin-Ⅰ(TNI) Colloidal gold colloid immunochromatography assay(CGCIA) Latex enhanced immunoturbidimetric assay(LEITD) Chemiluminesence immunoassay(CLIA) Performance evaluation
  • 相关文献

参考文献9

二级参考文献42

  • 1敬华,李丹,王晓非,陈兴明,高铁山,杨晋德,魏萍.几种心肌损伤标志物对急性心肌梗死的诊断效率[J].中国实验诊断学,2006,10(3):258-261. 被引量:27
  • 2杨振华,中华医学杂志,1995年,75卷,69页
  • 3Panteghini M, Apple FS, Christenson RH, et al. Proposal from IFCC committee on standardization of markers of cardiac damage (C- SMCD) :Recommendation on use of biochemical markers of cardiac damage in acute coronary syndromes. Scan J Clin Lab Invest, 1999,59(Suppl 230): 103~ 112.
  • 4Wu AHB, Apple FS, Gibler WB, et al. National Academy of Clinical Biochemistry standards of laboratory practice: recommendations for the use of cardiac markers in coronary artery diseases. Clin Chem, 1999,45:1104~1121.
  • 5Ravkilde J. Risk stratification in acute coronary syndrome using cardiac troponin Ⅰ. Clin Chem, 2000,46: 443~ 444.
  • 6Datta P, Foster K, Dasgupta A. Comparison of immunoreactivity of five human cardiac troponin Ⅰ assay toward free and complexed forms of the antigen: implications for assay discordance. Clin Chem, 1999,45: 2266~ 2269.
  • 7Reiffert S,Jaquet K,Helimeyer L, et al. Stepwise subunit interaction changes by mono - and bisphosphorylation of cardiac troponin Ⅰ. Biochemistry, 1998,37:13516~13525.
  • 8Leszyk J, Dumaswala R, Ported JD. Amino acid sequence of bovine cardiac troponin Ⅰ. Biochemistry, 1988,27:1105~ 1112.
  • 9Vallins WJ, Brand NJ, Dabhade N, et al. Molecular cloning of human cardiac troponin Ⅰ using polymerase chain reaction. FEBS Lett, 1990,270: 57 ~ 61.
  • 10Wu AHB. Biochemical markers of cardiac damage: from traditional enzymes to cardiac - specific proteins. Scand J Clin Lab Invest, 1999,59(Suppl 230): 74~ 82.

共引文献162

同被引文献36

引证文献4

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部